Road of no return — loss of TP53 paves a defined evolution path from gastric preneoplasia-to-cancer

An, Liwei; Han, Yi; Jiao, Shi; Zhou, Zhaocai

doi:10.20892/j.issn.2095-3941.2023.0435

Cited by 1 publication

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gastric adenocarcinomas can originate from both stem cells and terminal differentiated cells located at the cardia, corpus, and antrum of the stomach. Furthermore, genetic mutations such as inactivation of tumor suppressors, including RNF43 25 , TP53 26 , 27 , and ROHA 10 , 28 , as well as activation of oncogenic Kras 29 and YAP 30 , synergistically initiate and drive the tumor evolution of GC. Among them, the Hippo signaling pathway has been extensively investigated as a major driving force of both gastric tumorigenesis and acquired drug resistance 31 , 32 .…”

Section: Introductionmentioning

confidence: 99%

Modeling human gastric cancers in immunocompetent mice

Zhang,

Wang,

Zhang

et al. 2024

Cancer Biol Med

View full text Add to dashboard Cite

Gastric cancer (GC) is a major cause of cancer-related mortality worldwide. This cancer is determined by multiple (epi)genetic and environmental factors; can occur at distinct anatomic positions of the stomach; and displays high heterogeneity, with different cellular origins and diverse histological and molecular features. This heterogeneity has hindered efforts to fully understand the pathology of GC and develop efficient therapeutics. In the past decade, great progress has been made in the study of GC, particularly in molecular subtyping, investigation of the immune microenvironment, and defining the evolutionary path and dynamics. Preclinical mouse models, particularly immunocompetent models that mimic the cellular and molecular features of human GC, in combination with organoid culture and clinical studies, have provided powerful tools for elucidating the molecular and cellular mechanisms underlying GC pathology and immune evasion, and the development of novel therapeutic strategies. Herein, we first briefly introduce current progress and challenges in GC study and subsequently summarize immunocompetent GC mouse models, emphasizing the potential application of genetically engineered mouse models in antitumor immunity and immunotherapy studies.

show abstract